Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells

Cancer Biology and Therapy

Volumn 11, Issue 4, 2011, Pages 395-400

  Jia, Zheng Cai ^a   Tian, Yi ^a   Huang, Ze Min ^a   Wang, Jing Xue ^a   Fu, Xiao Lan ^a   Ni, Bing ^a   Wu, Yu Zhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer testis antigen; CTL; Epitope; HLA A*0201; Immunotherapy; MAGE A10; Tumor

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GLYCYLLEUCYLTYROSYLASPARTYLGLYCYLMETHIONYLGLUTAMYLHISTIDYLLEUCINE; HLA A ANTIGEN; ISOLEUCYLLEUCYLISOLEUCYLLEUCYLSERYLISOLEUCYLISOLEUCYLPHENYLALANYLISOLEUCINE; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 10 310-318; METHIONYLLEUCYLLEUCYLVALYLPHENYLALANYLGLYCYLISOLEUCYLASPARTYLVALINE; PEPTIDE VACCINE; SERYLLEUCYLLEUCYLLYSYLPHENYLALANYLLEUCYLALANYLLYSYLVALINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN TARGETING; TRANSGENIC MOUSE; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79951816416     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.4.14100     Document Type: Article

References (30)

1. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40:360-9. (Pubitemid 24299325)
2. Rogner UC, Wilke K, Steck E, Korn B, Poustka A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 1995; 29:725-31.
3. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000; 85:460-5. (Pubitemid 30075121)
4. Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009; 125:1365-71.
5. Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Löning T, Jänicke F, et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001; 61:6682-7. (Pubitemid 32896486)
6. Tsai JR, Chong IW, Chen YH, Yang MJ, Sheu CC, Chang HC, et al. Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer 2007; 56:185-92.
7. Li J, Yang Y, Fujie T, Baba K, Ueo H, Mori M, et al. Expression of BAGE, GAGE and MAGE genes in human gastric carcinoma. Clin Cancer Res 1996; 2:1619-25.
8. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, et al. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 1996; 24:1437-40. (Pubitemid 26399046)
9. Jungbluth AA, Silva WA Jr, Iversen K, Frosina D, Zaidi B, Coplan K, et al. Expression of cancer-testis (CT) antigens in placenta. Cancer Immun 2007; 7:15.
10. Tanaka F, Haraguchi N, Isikawa K, Inoue H, Mori M. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep 2008; 20:1111-6.
11. van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 23:9008-21. (Pubitemid 46211485)
12. Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219-30. (Pubitemid 29001725)
13. Lin J, Lin L, Thomas DG, Greenson JK, Giordano TJ, Robinson GS, et al. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res 2004; 10:5708-16. (Pubitemid 39180946)
14. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, et al. Cancer/testis antigen expression and specific cytotoxic T-lymphocyte responses in non small cell lung cancer. Int J Cancer 2007; 120:337-43. (Pubitemid 44956843)
15. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12:5442-7. (Pubitemid 44497259)
16. Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva WA Jr, Zago MA. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 2006; 28:614-9. (Pubitemid 44025110)
17. + T cell responses in patients with hepatocellular carcinoma. J Immunol 2005; 174:1709-16.
18. Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Liénard D, Guillaume P, et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 2001; 61:509-12.
19. Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 1999; 29:3329-37. (Pubitemid 29484224)
20. Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, et al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 1999; 162:6849-54. (Pubitemid 29309414)
21. Tang Y, Lin Z, Ni B, Wei J, Han J, Wang H, et al. An altered peptide ligand for naïve cytotoxic T-lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity. Cancer Immunol Immunother 2007; 56:319-29.
22. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13:529-38.
23. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002; 2:514-20. (Pubitemid 37336518)
24. + T cell efficacy in vaccination and disease. Nat Med 2008; 14:623-8.
25. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000; 30:3411-21. (Pubitemid 32005212)
26. Huppa JB, Gleimer M, Sumen C, Davis MM. Continuous T-cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 2003; 4:749-55. (Pubitemid 36986758)
27. Peng JR, Chen HS, Mou DC, Cao J, Cong X, Qin LL, et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 2005; 219:223-32. (Pubitemid 40269487)
28. Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?. J Cancer Res Clin Oncol 2003; 129:397-409. (Pubitemid 36995139)
29. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993; 23:1215-9. (Pubitemid 23165680)
30. Shinohara ML, Jansson M, Hwang ES, Werneck MB, Glimcher LH, Cantor H. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci USA 2005; 102:17101-6. (Pubitemid 41692690)